Haleon PLC Sponsored ADR ( (HLN) ) has provided an announcement.
On April 28, 2025, Haleon PLC announced the purchase of 861,136 ordinary shares for cancellation as part of its share buyback program initiated on March 28, 2025. This transaction, completed on April 25, 2025, reflects Haleon’s strategic move to optimize its capital structure and potentially enhance shareholder value. Following this transaction, the company’s registered share capital stands at 9,023,600,136 ordinary shares, with 9,019,519,931 shares carrying voting rights, impacting shareholder notifications under FCA rules.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.
Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Its well-known brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum are recognized for their trusted science, innovation, and deep human understanding.
YTD Price Performance: 7.93%
Average Trading Volume: 11,592,265
Technical Sentiment Signal: Sell
Current Market Cap: $45.23B
For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.